This round of financing is led by Yuanxin Technology Group and followed by Xiangrafter Capital.
Recently, Lekang Jiarun Biomedical Technology (Hangzhou) Co., Ltd. (hereinafter referred to as "Lekang Jiarun") announced the completion of tens of millions of yuan in angel round financing. This round of financing is led by Yuanxin Technology Group and followed by Xiangrafter Capital. The funds will be used for the research and development of innovative drugs to improve the team and market expansion capabilities. Founded in March 2022, Lekang Jarun is mainly engaged in the R&D and market development of anti-tumor drugs, clinical resource management, and service application of innovative drugs, and has built a full chain industry of "patient recruitment+patient management+tumor medical services". Through close cooperation with domestic brand pharmaceutical chain enterprises, medical clinics and Internet pharmaceutical platforms, the company has built a national sales network covering more than 70 commercial companies and more than 10000 pharmacies. Lekang Jarun is committed to becoming a first-class pharmaceutical group company with R&D and sales in China. As the main body of innovative drug research and development, Hangzhou Baiyintai Pharmaceutical Technology Co., Ltd., a subsidiary of Lekang Jarun, takes innovative preparations as the core technology, and has established a technical platform for anti-tumor platinum prodrug, nucleic acid drug delivery system Three new drug R&D platforms for polypeptide non injection preparation technology platform. Hangzhou Baiyintai hired Professor Zhang Qiang, an academician of the Chinese Academy of Engineering, Vice Dean of the School of Pharmacy of Peking University, as a strategic consultant for new drug research and development.
